Australian Clinical Labs (ASX:ACL) EBIT : A$28.2 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs EBIT?

Australian Clinical Labs's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was A$10.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was A$28.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Australian Clinical Labs's annualized ROC % for the quarter that ended in Dec. 2023 was 5.13%. Australian Clinical Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 7.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Australian Clinical Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.73%.

Australian Clinical Labs EBIT Historical Data

The historical data trend for Australian Clinical Labs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs EBIT Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

EBIT

97.59

256.24

51.85

Australian Clinical Labs Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial			185.71	70.53	33.91	17.94	10.24

Competitive Comparison of Australian Clinical Labs's EBIT

For the Diagnostics & Research subindustry, Australian Clinical Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's EV-to-EBIT falls into.

Australian Clinical Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$28.2 Mil.

Australian Clinical Labs (ASX:ACL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Australian Clinical Labs's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	47.95 * ( 1 - 34.99% )	/	( (609.515	+	606.711)	/ 2 )
=	31.172295	/	608.113
=	5.13 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	578.913	-	41.364	-	( 19.955	-	max(0, 187.925	-	115.959	+	19.955	))
=	609.515

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	583.723	-	41.243	-	( 24.938	-	max(0, 189.992	-	125.761	+	24.938	))
=	606.711

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Australian Clinical Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	20.47	/	( ( (288.438 + max(-13.194, 0))	+	(281.158 + max(12.605, 0)) )	/	2 )
=	20.47	/	( ( 288.438	+	293.763 )	/	2 )
=	20.47	/	291.1005
=	7.03 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(51.352	+	15.092	+	7.202)	-	(41.364	+	0.008	+	45.468)
=	-13.194

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(74.138	+	16.805	+	9.88)	-	(41.243	+	1.16	+	45.815)
=	12.605

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Australian Clinical Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	28.176	/	756.223
	=	3.73 %

Australian Clinical Labs EBIT Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs (ASX:ACL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines